AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16187513 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-deficient noncoper group
Number of subjects: 15
Study 16187513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 14515935 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength-training programme
Number of subjects: 21
Study 14515935 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 10782658 — intervention group
Group type: EXPERIMENTAL
Intervention: > 0 and <= 10 g of alcohol/day
Number of subjects: 1336
Study 10782658 — intervention group
Group type: EXPERIMENTAL
Intervention: > 10 and <= 20 g/day
Number of subjects: 1336
Study 10782658 — intervention group
Group type: EXPERIMENTAL
Intervention: > 20 and <= 30 g/day
Number of subjects: 1336
Study 10782658 — intervention group
Group type: EXPERIMENTAL
Intervention: > 30 and <= 40 g/day
Number of subjects: 1336
Study 10782658 — intervention group
Group type: EXPERIMENTAL
Intervention: > 40 and <= 50 g/day
Number of subjects: 1336
Study 10782658 — intervention group
Group type: EXPERIMENTAL
Intervention: > 50 g/day
Number of subjects: 1336
Study 8873656 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated tissue plasminogen activator (TPA) plus intravenous heparin
Number of subjects: 0
Study 8873656 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase plus subcutaneous heparin
Number of subjects: 0
Study 8873656 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase plus intravenous heparin
Number of subjects: 0
Study 8873656 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase and TPA plus intravenous heparin
Number of subjects: 0
Study 1642941 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.65-0.75%)
Number of subjects: 8
Study 1642941 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (60-65%)
Number of subjects: 8
Study 6342701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 0
Study 6342701 — intervention group
Group type: COMPARATOR
Intervention: Fatty meal
Number of subjects: 0
Study 6342701 — intervention group
Group type: COMPARATOR
Intervention: Solubiloptin following Biloptin
Number of subjects: 0
Study 6342701 — intervention group
Group type: COMPARATOR
Intervention: Biloptin
Number of subjects: 0
Study 31045669 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block and periarticular injection
Number of subjects: 111
Study 31045669 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection
Number of subjects: 111
Study 29426387 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-PID (Collaborative Consultation for Participation of Students With Intellectual Disability)
Number of subjects: 60
Study 29426387 — intervention group
Group type: COMPARATOR
Intervention: In-Service (IS)
Number of subjects: 60
Study 27912776 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit of quality improvement interventions including provider-focused strategies (education, audit and feedback, electronic decision support, reminders) and patient-directed strategies (educational letters, reminders)
Number of subjects: 0
Study 27912776 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study 24431443 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG activity during face detection task
Number of subjects: 0
Study 22578258 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated threshold ROP patients (group 1)
Number of subjects: 133
Study 22578258 — intervention group
Group type: COMPARATOR
Intervention: Regressed ROP patients (group 2)
Number of subjects: 133
Study 22578258 — intervention group
Group type: COMPARATOR
Intervention: Premature patients without ROP (group 3)
Number of subjects: 133
Study 22578258 — intervention group
Group type: COMPARATOR
Intervention: Normal full-term children (group 4)
Number of subjects: 133
Study 19047294 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose induction chemotherapy (cytarabine, daunorubicin, and 6-thioguanine)
Number of subjects: 1284
Study 19047294 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction chemotherapy (cytarabine and mitoxantrone)
Number of subjects: 1284
Study 19047294 — intervention group
Group type: COMPARATOR
Intervention: High-dose combination (two courses)
Number of subjects: 1284
Study 17459189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 11
Study 17459189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk with added 20 mmol/l NaCl
Number of subjects: 11
Study 17459189 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study 17459189 — intervention group
Group type: COMPARATOR
Intervention: Sports drink
Number of subjects: 11
Study 16425789 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily for 6 weeks
Number of subjects: 35
Study 16425789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily for 6 weeks
Number of subjects: 35
Study 16425789 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 clinically healthy subjects with no CHD risk factors)
Number of subjects: 35
Study 12002729 — intervention group
Group type: EXPERIMENTAL
Intervention: 120mg Fexofenadine (FEX)
Number of subjects: 37
Study 12002729 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg Montelukast (ML) + 10mg Loratadine (LT)
Number of subjects: 37
Study 12002729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study 10213063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal flap surgery with different flap widths
Number of subjects: 53
Study 7875470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic activation (induced by lower body negative pressure)
Number of subjects: 9
Study 7875470 — intervention group
Group type: COMPARATOR
Intervention: No sympathetic activation
Number of subjects: 9
Study 1923171 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0
Study 1923171 — intervention group
Group type: COMPARATOR
Intervention: No transdermal scopolamine (Control)
Number of subjects: 0
Study 7040956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion for 48 hours
Number of subjects: 812
Study 7040956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study 7040956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion started within nine hours of onset of pain
Number of subjects: 812
Study 7040956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion started later than nine hours of onset of pain
Number of subjects: 812
Study 31793890 — intervention group
Group type: EXPERIMENTAL
Intervention: YouthCHAT
Number of subjects: 129
Study 31793890 — intervention group
Group type: COMPARATOR
Intervention: HEEADSSS
Number of subjects: 129
Study 29368902 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula officinalis diluted 10% as an irrigant during surgical extraction and mouthwash for a week after extraction.
Number of subjects: 0
Study 29368902 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as an irrigant during surgical extraction and mouthwash for a week after extraction.
Number of subjects: 0
Study 27118687 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 9270
Study 25132069 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass
Number of subjects: 32
Study 25132069 — intervention group
Group type: COMPARATOR
Intervention: Normal weight control
Number of subjects: 32
Study 22249475 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of retinol every four months
Number of subjects: 213
Study 22249475 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation for 10 days
Number of subjects: 213
Study 22249475 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (40 mg twice weekly)
Number of subjects: 213
Study 22249475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both retinol and zinc
Number of subjects: 213
Study 22249475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in apolipoprotein E4(+) children
Number of subjects: 213
Study 22249475 — intervention group
Group type: COMPARATOR
Intervention: Apolipoprotein E4(‐) children (regardless of intervention)
Number of subjects: 213
Study 18484198 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (four cycles of fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 698
Study 17154437 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam test formulation from Ranbaxy Laboratories Ltd (2 mg)
Number of subjects: 0
Study 17154437 — intervention group
Group type: COMPARATOR
Intervention: Rivotril from Roche Laboratórios Ltda (2 mg)
Number of subjects: 0
Study 15688960 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily flossing regime
Number of subjects: 39
Study 15688960 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush alone
Number of subjects: 39
Study 12208408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg over 10 minutes)
Number of subjects: 25
Study 12208408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg over 5 minutes)
Number of subjects: 25
Study 12208408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (after crossover)
Number of subjects: 25
Study 12208408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (after crossover)
Number of subjects: 25
Study 12208408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone and/or Ibutilide
Number of subjects: 25
Study 9803987 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg) with ferrous sulphate (300 mg)
Number of subjects: 7
Study 7648804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 30
Study 7648804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2930250 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm carbon monoxide (CO)
Number of subjects: 10
Study 2930250 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm carbon monoxide (CO)
Number of subjects: 10
Study 2930250 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study 105825 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 32
Study 105825 — intervention group
Group type: COMPARATOR
Intervention: ICI 74,917
Number of subjects: 32
Study 30678165 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (age, weight, height, BMI)
Number of subjects: 2225
Study 30678165 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (raw BIA variables: bioimpedance-index and phase angle)
Number of subjects: 2225
Study 30678165 — intervention group
Group type: EXPERIMENTAL
Intervention: Equations developed for BMI categories
Number of subjects: 2225
Study 27927884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated zirconia abutment with pressed ceramic (Group A)
Number of subjects: 40
Study 27927884 — intervention group
Group type: COMPARATOR
Intervention: CAD/CAM zirconia abutment with hand buildup technique (Group B)
Number of subjects: 40
Study 27927884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26469515 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (humans)
Number of subjects: 29
Study 26469515 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (humans)
Number of subjects: 29
Study 26469515 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (mice)
Number of subjects: 29
Study 26469515 — intervention group
Group type: COMPARATOR
Intervention: Control diet (mice)
Number of subjects: 29
Study 24193079 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Engagement Video (DEV)
Number of subjects: 925
Study 24193079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Multimedia Computer Program (IMCP)
Number of subjects: 925
Study 24193079 — intervention group
Group type: COMPARATOR
Intervention: Control (Sleep Hygiene Video)
Number of subjects: 925
Study 24193079 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed Patients (PHQ-8 score at 12-week follow-up)
Number of subjects: 925
Study 24193079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed Patients (Clinician-reported antidepressant prescribing)
Number of subjects: 925
Study 24193079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed Patients (Patient-reported antidepressant recommendation)
Number of subjects: 925
Study 20421153 — intervention group
Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 300
Study 20421153 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 300
Study 19644849 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg plus MTX
Number of subjects: 637
Study 19644849 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus MTX
Number of subjects: 637
Study 19644849 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus placebo
Number of subjects: 637
Study 19644849 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 637
Study 19644849 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined golimumab groups (50 mg + MTX and 100 mg + MTX)
Number of subjects: 637
Study 17605597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched post-discharge formula (PDF)
Number of subjects: 20
Study 17605597 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula (TF)
Number of subjects: 20
Study 17605597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PDF and TF)
Number of subjects: 20
Study 14665448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.0 mg orally
Number of subjects: 16
Study 11703573 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (IFN)
Number of subjects: 62
Study 9380826 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft immobilization device supporting the lower legs and polycarbonate insert
Number of subjects: 61
Study 9380826 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment couch
Number of subjects: 61
Study 9380826 — intervention group
Group type: COMPARATOR
Intervention: Table top stiffened using a 1 cm polycarbonate insert
Number of subjects: 61
Study 7898001 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of antibiotics for treatment of the recurrence
Number of subjects: 11
Study 7898001 — intervention group
Group type: EXPERIMENTAL
Intervention: biseptol + glucocorticoids
Number of subjects: 11
Study 2954026 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA supplementation
Number of subjects: 39
Study 2954026 — intervention group
Group type: COMPARATOR
Intervention: No DHA supplementation (Control)
Number of subjects: 39
Study 31267277 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology intervention (4 weekly sessions, 30-min protocol)
Number of subjects: 256
Study 31267277 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 256
Study 28960520 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 0.5%/salicylic acid 10%
Number of subjects: 27
Study 28960520 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 27
Study 26972584 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4
Number of subjects: 138
Study 26972584 — intervention group
Group type: COMPARATOR
Intervention: EU‐ETN
Number of subjects: 138
Study 25424947 — intervention group
Group type: EXPERIMENTAL
Intervention: A/H1N1 vaccine formulations with varying antigen quantity (3.75 µg to 30 µg of hemagglutinin) and MF59(®) adjuvant (none, half dose, or full dose)
Number of subjects: 2592
Study 25424947 — intervention group
Group type: EXPERIMENTAL
Intervention: A single vaccine dose containing 3.75 µg of A/California/7/2009 (H1N1) antigen with MF59 adjuvant
Number of subjects: 2592
Study 24360042 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified balloon dilatation and traditional swallowing therapy (E-stim, Mendelsohn Maneuver, supraglottic swallowing) for 3 weeks
Number of subjects: 30
Study 24360042 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing therapy for 3 weeks
Number of subjects: 30
Study 21827440 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg (group SP2)
Number of subjects: 104
Study 21827440 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1 mg/kg (group SP1)
Number of subjects: 104
Study 18279736 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment triglycerides (TG) <150 mg/dl
Number of subjects: 4162
Study 18279736 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10 mg/dl decrement in on-treatment TG
Number of subjects: 4162
Study 18279736 — intervention group
Group type: EXPERIMENTAL
Intervention: TG <150 mg/dl and LDL-C <70 mg/dl
Number of subjects: 4162
Study 18279736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low on-treatment TG, LDL-C, and C-reactive protein (<2 mg/l)
Number of subjects: 4162
Study 16545135 — intervention group
Group type: EXPERIMENTAL
Intervention: Random gentamicin concentration measured 4-20 hours after administration
Number of subjects: 50
Study 16545135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram validation in 39 further babies, median gestation 34 weeks (28-41)
Number of subjects: 50
Study 16545135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurity indicator (< or = 37 weeks)
Number of subjects: 50
Study 16545135 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm babies
Number of subjects: 50
Study 15023597 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat diet (HM) - 34% protein, 46% carbohydrate, 20% fat
Number of subjects: 100
Study 15023597 — intervention group
Group type: COMPARATOR
Intervention: Low meat diet (LM) - 17% protein, 64% carbohydrate, 20% fat
Number of subjects: 100
Study 15023597 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat diet (HM) for subjects with high triglycerides (>1.5mmol/L)
Number of subjects: 100
Study 10919421 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion
Number of subjects: 40
Study 10919421 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 40
Study 8706601 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour-flow echocardiography
Number of subjects: 1115
Study 1433454 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breastmilk (EBM)
Number of subjects: 50
Study 1433454 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk formula
Number of subjects: 50
Study 1433454 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral feeding
Number of subjects: 50
Study 2987445 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning style assessment (experimental group)
Number of subjects: 60
Study 2987445 — intervention group
Group type: COMPARATOR
Intervention: Cognitive style mapping assessment (control group)
Number of subjects: 60
Study 31759770 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven (fish oil) supplementation for 4 weeks
Number of subjects: 12
Study 31759770 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven (fish oil) supplementation
Number of subjects: 12
Study 31759770 — intervention group
Group type: COMPARATOR
Intervention: Smoflipid regimen
Number of subjects: 12
Study 31759770 — intervention group
Group type: COMPARATOR
Intervention: Lipoplus regimen
Number of subjects: 12
Study 31759770 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 31759770 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated production of IL-6
Number of subjects: 12
Study 30387900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral and common peroneal nerve blocks with 0.33% ropivacaine
Number of subjects: 40
Study 30387900 — intervention group
Group type: COMPARATOR
Intervention: Sham blocks with saline
Number of subjects: 40
Study 27871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased admission glucose
Number of subjects: 335
Study 27871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia on admission
Number of subjects: 335
Study 27871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 335
Study 26982667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Pheniramine hydrogen maleate (8mg/2ml + 45.5/2ml)
Number of subjects: 120
Study 26982667 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 ml)
Number of subjects: 120
Study 22018049 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-SM (0.1% dairy fat)
Number of subjects: 43
Study 22018049 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-VFM (0.1% dairy fat plus 1.5% vegetable fat)
Number of subjects: 43
Study 22018049 — intervention group
Group type: COMPARATOR
Intervention: Control SM
Number of subjects: 43
Study 22018049 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-SM and PS-VFM
Number of subjects: 43
Study 19707025 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral probiotics supplementation
Number of subjects: 1425
Study 19707025 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 1425
Study 18073378 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole for 3 years
Number of subjects: 856
Study 18073378 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 856
Study 16282845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 36
Study 16282845 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 36
Study 12383143 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence care and exercise intervention (provided every 2 hours from 8:00 a.m. to 4:00 p.m. 5 days a week)
Number of subjects: 256
Study 12383143 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 256
Study 10514772 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety influence on cognitive processes during exams
Number of subjects: 0
Study 10514772 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological symptoms perception
Number of subjects: 0
Study 7564674 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg weekly (days 1, 8, and 15)
Number of subjects: 226
Study 7564674 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline eye ointment (days 1-42)
Number of subjects: 226